logo
AI Icon𝛼SK or Search
ENTITY
Daiichi Sankyo

Daiichi Sankyo (4568 JP)

281
Analysis
Health Care • Japan
Daiichi Sankyo Co, Ltd is a holding company established through merger of Sankyo and Daiichi pharmaceutical. The Group manufactures pharmaceuticals for human/veterinary use and medical tools and equipment. It also researches and promotes products through related companies throughout the world. The Group also produces food, food additives, livestock feeds, and agrochemicals.
more
bearish•Duality Biotherapeutics
•04 Jun 2026 08:30

Duality Biotherapeutics (9606 HK): Core Product Pipeline Is Progressing; Share Buyback Announced

​Duality Bio is advancing core products towards commercialization, but faces competition for market adoption. Amid multiple catalysts in 2026 for...

Logo
Tina Banerjee
134 Views
Share
bullish•Quantitative Analysis
•01 Jun 2026 10:06

MS-Japan Index Earning Revision (May): Mitsubishi, Takeda Pharmaceutical, Mitsubishi UFJ Financial

We analyzed MS-Japan's consensus for May 2026 and highlighted changes of EPS in Mitsubishi, Takeda Pharmaceutical, Mitsubishi UFJ Financial, Orix,...

Logo
Ke Yan, CFA, FRM
134 Views
Share
bullish•Thematic (Sector/Industry)
•18 Dec 2018 14:43

Japan Pharma - Top Picks

While Gni Group Ltd (2160 JP) is our high risk-high return pick, Mitsubishi Tanabe Pharma (4508 JP)  is a contrarian call in anticipation of value...

Logo
Share
bullish•Thematic (Sector/Industry)
•28 Sep 2018 18:05

Japan CAR-T Therapy Landscape

Japan CAR-T therapy - Competitive landscapeJapan pharma catching-up with global players… but a large gap remains Novartis AG (NOVN SE)’ Kymriah...

Logo
Share
bullish•Thematic (Sector/Industry)
•25 Sep 2018 19:48

Japan Pharma: Core Coverage Investment Thesis and Valuations (III/​III)

Takeda Pharmaceutical (4502 JP), Astellas Pharma (4503 JP), Daiichi Sankyo (4568 JP), Eisai Co Ltd (4523 JP), Otsuka Holdings (4578 JP), Chugai...

Logo
Share

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x